Carbon Reduction Plan

Supplier Name: medac Pharma LLP

Publication date: 08/07/2026

Commitment to achieving net zero
medac Pharma LLP is committed to achieving net zero emissions by 2045.

Baseline emissions footprint
Baseline emissions are a record of the greenhouse gases that have been produced in the past and were produced prior to the introduction of any strategies to reduce emissions. Baseline emissions are the reference point against which emissions reduction can be measured.

Baseline Year and Current emissions footprint

Reporting Year: 2025/2026	
Additional Details relating to the Baseline Emissions calculations	
Although we have previously measured scope 1, 2 and a subset of scope 3 emissions, in 2025/2026, all relevant scope 3 emissions were included in the measurement due to updated requirements for NHS suppliers. As full scope 3 data was not available for the 2022/2023 base year, and the additional scope 3 emissions were significant, medac Pharma LLP has set a new baseline year of 2025/2026.	
Emissions	**Total (tCO_2e)**
Scope 1	**3.80**
Scope 2	**1.08**
Scope 3 (included sources)	**18,010.15**
3.1 Purchased goods and services	15,277.73
3.2 Capital goods	10.41
3.3 Fuel- and energy-related activities	1.02
3.4 Upstream transportation and distribution	2,248.78
3.5 Waste generated in operations	3.42
3.6 Business travel	127.16
3.7 Employee commuting	90.11
3.9 Downstream Transportation and Distribution	79.55
3.12 End-of-life treatment of sold products	85.47
3.15 Investments	86.52

3.8 - 3.11, 3.13, 3.14	Not relevant
Total Emissions	**18,015.03**

Emissions reduction targets

medac Pharma LLP has now expanded the scope of its greenhouse gas inventory to include all relevant scope 3 emissions categories. Previous reporting was limited to scope 1, 2 and a subset of scope 3 categories, which included Upstream Transportation, Waste Disposal, Business Travel, Employee Commuting, and Downstream Distribution. This was sufficient for the previous Carbon Reduction Plan requirements, but does not reflect the full value chain emissions now required for a more complete scope 3 calculation.

The most significant change as a result of the updated boundaries is the inclusion of Purchased Goods and Services emissions. The majority of emissions in this category have come from the purchasing of pharmaceuticals from our parent company, medac GmbH. As a result, total reported emissions have increased significantly from previous years.

For this reason, medac Pharma LLP has set 2025/2026 as the new baseline year for its updated targets, in order to provide a more accurate and complete basis for future carbon reduction planning and target tracking.

medac Pharma LLP commits to reducing scope 1, 2 and 3 emissions by 30% by 2030 from a 2025 baseline.

medac Pharma LLP commits to reducing scope 1, 2 and 3 emissions by 90% by 2045 from a 2025 baseline and removing the remaining 10% with high quality carbon removals.

The targeted emissions trajectory can be seen in the graph below:



Carbon reduction projects

Completed carbon reduction initiatives

The following environmental management measures and projects have been completed or implemented.

- Switch to a 70% renewable energy supplier for the office
- Introduction of DocuSign to reduce printing and save paper
- Hybrid working, home working and virtual meetings: lessening commuting and
- business travel
- Engage with the supply chain both domestic and international to ensure commitment
- to environmental plans and projects – Net Zero by 2045
- Segregating and recycling of all office waste
- Employee Engagement – ongoing regular bulletin uploads on company intranet with
- information on key sustainable dates
- Employee Education – ongoing E-learning sustainability modules completed by all
- employees
- Encouraging employees to use public transport where possible to attend both internal and external meetings

Future carbon reduction initiatives

In future reporting periods, medac Pharma LLP will focus on reducing emissions across the categories that have the greatest influence on its total footprint. In the future we hope to implement further measures such as:

- Engaging with our parent company, medac GmbH, to understand and influence the emissions intensity of purchased pharmaceutical products
- Review outbound logistics arrangements to identify opportunities for lower carbon transport modes or route optimisation

- Explore consolidation of shipments to reduce the frequency and distance of outbound deliveries
- Introduce a travel policy prioritising rail over air

Declaration and sign off

This Carbon Reduction Plan has been completed in accordance with PPN 006 and associated guidance and reporting standard for Carbon Reduction Plans.
Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard[13] and uses the appropriate government emission conversion factors for greenhouse gas company reporting.[14]

Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements (where required), and the required subset of Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard.[15]

This Carbon Reduction Plan has been reviewed and signed off by the board of directors (or equivalent management body).

Signed on behalf of the supplier:

....

Date: 08/07/2026

[13] https://ghgprotocol.org/corporate-standard
[14] www.gov.uk/government/collections/government-conversion-factors-for-company-reporting [15] https://ghgprotocol.org/standards/scope-3-standard